Eliglustat - 98% , high purity , CAS No.491833-29-5

Item Number

E413855

• Synonyms: EN300-259910 | Genz 99067 | s7852 | 1000191-50-3 | CCG-101413 | CHEBI:82752 | Genz-99067 | Z825742124 | GLXC-90436 | AC-35323 | F53213 | DB09039 | N-((1R,2R)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)octanamide | STL
• Specifications & Purity: Moligand™, ≥98%
• Biochemical and Physiological Mechanisms: Eliglustat (GENZ-112638) inhibits glucosylceramide synthase(GCS) (IC50=20 nM in intact MDCK cells), thus reducing the load of glucosylceramide influx into the lysosome.
• Storage Temp: Store at -20°C
• Shipped In: Ice chest + Ice pads
• Grade: Moligand™

Product Description

Information

Eliglustat Eliglustat (GENZ-112638) inhibits glucosylceramide synthase(GCS) (IC50=20 nM in intact MDCK cells), thus reducing the load of glucosylceramide influx into the lysosome.

Targets

glucosylceramide synthase (In intact MDCK cells) 20 nM

In vitro

Eliglustat tartrate is designed and developed to inhibit glucosylceramide synthase, the enzyme that catalyzes the formation of glucosylceramide from UDP-glucose and ceramide.The inhibition of glucosylceramide synthase by eliglustat tartrate is highly specific. Eliglustat tartrate displays limited or no activity against a variety of glycosidases. Additionally, no inhibition of sucrase or maltase is observed at drug concentrations up to 10 μM.

In vivo

Preclinical studies in normal mice, rats and dogs with i.v. and oral administration demonstrates significant dose-related decreases in spleen, kidney and liver glucosylceramide content, consistent with prior observations with the palmitoyl homologue.In rodents, Genz-112638 is rapidly metabolized with a half-life of 15–45 minutes.